Who is sponsoring NCT01713530?

NCT01713530 is sponsored by Novo Nordisk A/S.

What condition does NCT01713530 study?

NCT01713530 studies Diabetes, Diabetes Mellitus, Type 2.

What drugs are being tested in NCT01713530?

Interventions: insulin degludec/insulin aspart, insulin degludec, insulin aspart.

What is the status of NCT01713530?

NCT01713530 is currently COMPLETED.

Last reviewed 2018-04-02 · How we verify

A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

NCT01713530 PHASE3 COMPLETED Results posted

This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare the difference in change in glycosylated haemoglobin (HbA1c) between insulin degludec/insulin aspart (IDegAsp) and/or oral anti-diabetic drugs (OADs) and insulin degludec (IDeg) plus insulin aspart (IAsp)and/or OADs.

Details

Lead sponsor	Novo Nordisk A/S
Phase	PHASE3
Status	COMPLETED
Enrolment	274
Start date	Thu Feb 21 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jan 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

insulin degludec/insulin aspart
insulin degludec
insulin aspart

Countries

France, Austria, Norway, Algeria, United States